Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 239

1.

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial.

Fischer K, Ritgen M, Al-Sawaf O, Robrecht S, Tandon M, Fink AM, Schilhabel A, Stübig T, Brüggemann M, Jiang Y, Schary W, Eichhorst BF, Wendtner CM, Tausch E, Kreuzer KA, Langerak AW, Goede V, Böttcher S, Stilgenbauer S, Kneba M, Hallek M.

Blood. 2019 Nov 13;134(Supplement_1):36. doi: 10.1182/blood-2019-125825.

PMID:
31724026
2.

A New and Simple TRG Multiplex PCR Assay for Assessment of T-cell Clonality: A Comparative Study from the EuroClonality Consortium.

Armand M, Derrieux C, Beldjord K, Wabeke T, Lenze D, Boone E, Bruggemann M, Evans PAS, Gameiro P, Hummel M, Villarese P, Groenen PJTA, Langerak AW, Macintyre EA, Davi F.

Hemasphere. 2019 Jun 4;3(3):e255. doi: 10.1097/HS9.0000000000000255. eCollection 2019 Jun.

3.

The presence of CLL-associated stereotypic B cell receptors in the normal BCR repertoire from healthy individuals increases with age.

Muggen AF, de Jong M, Wolvers-Tettero ILM, Kallemeijn MJ, Teodósio C, Darzentas N, Stadhouders R, IJspeert H, van der Burg M, van IJcken WF, Verhaar JAN, Abdulahad WH, Brouwer E, Boots AMH, Hendriks RW, van Dongen JJM, Langerak AW.

Immun Ageing. 2019 Aug 28;16:22. doi: 10.1186/s12979-019-0163-x. eCollection 2019.

4.

Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.

Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, Newman AM, Dührsen U, Hüttmann A, Casasnovas O, Westin JR, Ritgen M, Böttcher S, Langerak AW, Roschewski M, Wilson WH, Gaidano G, Rossi D, Bahlo J, Hallek M, Tibshirani R, Diehn M, Alizadeh AA.

Cell. 2019 Jul 25;178(3):699-713.e19. doi: 10.1016/j.cell.2019.06.011. Epub 2019 Jul 4.

PMID:
31280963
5.

Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.

Brüggemann M, Kotrová M, Knecht H, Bartram J, Boudjogrha M, Bystry V, Fazio G, Froňková E, Giraud M, Grioni A, Hancock J, Herrmann D, Jiménez C, Krejci A, Moppett J, Reigl T, Salson M, Scheijen B, Schwarz M, Songia S, Svaton M, van Dongen JJM, Villarese P, Wakeman S, Wright G, Cazzaniga G, Davi F, García-Sanz R, Gonzalez D, Groenen PJTA, Hummel M, Macintyre EA, Stamatopoulos K, Pott C, Trka J, Darzentas N, Langerak AW; EuroClonality-NGS working group.

Leukemia. 2019 Sep;33(9):2241-2253. doi: 10.1038/s41375-019-0496-7. Epub 2019 Jun 26.

6.

Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS.

Knecht H, Reigl T, Kotrová M, Appelt F, Stewart P, Bystry V, Krejci A, Grioni A, Pal K, Stranska K, Plevova K, Rijntjes J, Songia S, Svatoň M, Froňková E, Bartram J, Scheijen B, Herrmann D, García-Sanz R, Hancock J, Moppett J, van Dongen JJM, Cazzaniga G, Davi F, Groenen PJTA, Hummel M, Macintyre EA, Stamatopoulos K, Trka J, Langerak AW, Gonzalez D, Pott C, Brüggemann M, Darzentas N; EuroClonality-NGS Working Group.

Leukemia. 2019 Sep;33(9):2254-2265. doi: 10.1038/s41375-019-0499-4. Epub 2019 Jun 21.

7.

Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS.

Scheijen B, Meijers RWJ, Rijntjes J, van der Klift MY, Möbs M, Steinhilber J, Reigl T, van den Brand M, Kotrová M, Ritter JM, Catherwood MA, Stamatopoulos K, Brüggemann M, Davi F, Darzentas N, Pott C, Fend F, Hummel M, Langerak AW, Groenen PJTA; EuroClonality-NGS Working Group.

Leukemia. 2019 Sep;33(9):2227-2240. doi: 10.1038/s41375-019-0508-7. Epub 2019 Jun 13.

8.

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M.

N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4.

PMID:
31166681
9.

Responsiveness of Chronic Lymphocytic Leukemia cells to B cell receptor stimulation is associated with low expression of regulatory molecules of the Nuclear Factor-κB pathway.

Meijers RWJ, Muggen AF, Leon LG, de Bie M, van Dongen JJM, Hendriks RW, Langerak AW.

Haematologica. 2019 May 16. pii: haematol.2018.215566. doi: 10.3324/haematol.2018.215566. [Epub ahead of print]

10.

PCR GeneScan and Heteroduplex Analysis of Rearranged Immunoglobulin or T-Cell Receptor Genes for Clonality Diagnostics in Suspect Lymphoproliferations.

Boone E, Heezen KC, Groenen PJTA, Langerak AW; EuroClonality Consortium.

Methods Mol Biol. 2019;1956:77-103. doi: 10.1007/978-1-4939-9151-8_4.

PMID:
30779031
11.

Combined cellular and soluble mediator analysis for improved diagnosis of vitreoretinal lymphoma.

de Hoog J, Dik WA, Lu L, Heezen KC, Ten Berge JC, Swagemakers SMA, van der Spek PJ, van Dongen JJM, van der Velden VHJ, Rothova A, Langerak AW.

Acta Ophthalmol. 2019 Sep;97(6):626-632. doi: 10.1111/aos.14036. Epub 2019 Jan 27.

12.

Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.

Budde LE, Wu D, Martin DB, Philip M, Shustov AR, Smith SD, Gooley TA, Chen TL, Libby EN, Chen EY, Kojouri K, Langerak A, Roden JE, Press OW, Gopal AK.

Br J Haematol. 2018 Nov;183(4):601-607. doi: 10.1111/bjh.15585. Epub 2018 Sep 14.

13.

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.

Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ.

J Clin Oncol. 2019 Feb 1;37(4):269-277. doi: 10.1200/JCO.18.01580. Epub 2018 Dec 3.

14.

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation.

Agathangelidis A, Sutton LA, Hadzidimitriou A, Tresoldi C, Langerak AW, Belessi C, Davi F, Rosenquist R, Stamatopoulos K, Ghia P.

J Vis Exp. 2018 Nov 26;(141). doi: 10.3791/57787.

PMID:
30531723
15.

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.

Langerak AW, Ritgen M, Goede V, Robrecht S, Bahlo J, Fischer K, Steurer M, Trněný M, Mulligan SP, Mey UJM, Trunzer K, Fingerle-Rowson G, Humphrey K, Stilgenbauer S, Böttcher S, Brüggemann M, Hallek M, Kneba M, van Dongen JJM.

Blood. 2019 Jan 31;133(5):494-497. doi: 10.1182/blood-2018-03-839688. Epub 2018 Nov 19. No abstract available.

16.

Identification of Distinct Unmutated Chronic Lymphocytic Leukemia Subsets in Mice Based on Their T Cell Dependency.

Pal Singh S, de Bruijn MJW, de Almeida MP, Meijers RWJ, Nitschke L, Langerak AW, Pillai SY, Stadhouders R, Hendriks RW.

Front Immunol. 2018 Sep 13;9:1996. doi: 10.3389/fimmu.2018.01996. eCollection 2018.

17.

Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.

de Goeje PL, Klaver Y, Kaijen-Lambers MEH, Langerak AW, Vroman H, Kunert A, Lamers CHJ, Aerts JGJV, Debets R, Hendriks RW.

Front Immunol. 2018 Sep 7;9:2034. doi: 10.3389/fimmu.2018.02034. eCollection 2018.

18.

Flow cytometry shows added value in diagnosing lymphoma in brain biopsies.

van der Meulen M, Bromberg JEC, Lam KH, Dammers R, Langerak AW, Doorduijn JK, Kros JM, van den Bent MJ, van der Velden VHJ.

Cytometry B Clin Cytom. 2018 Nov;94(6):928-934. doi: 10.1002/cyto.b.21641. Epub 2018 Sep 3.

19.

Correction to: Circulating T Cells of Patients with Nijmegen Breakage Syndrome Show Signs of Senescence.

Meijers RWJ, Dzierzanowska-Fangrat K, Zborowska M, Solarska I, Tielemans D, van Turnhout BAC, Driessen G, van der Burg M, van Dongen JJM, Chrzanowska KH, Langerak AW.

J Clin Immunol. 2018 May;38(4):538. doi: 10.1007/s10875-018-0503-1.

20.

Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy.

van der Straten L, Dinmohamed AG, Westerweel PE, Langerak AW, Riedl J, Doorduijn JK, Kater AP, Levin MD.

Leuk Lymphoma. 2018 Nov;59(11):2757-2761. doi: 10.1080/10428194.2018.1452215. Epub 2018 Apr 4. No abstract available.

PMID:
29616852

Supplemental Content

Loading ...
Support Center